ReviewInflammatory bowel diseases2016
Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.
Review in Inflammatory bowel diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.Gastroenterology · 2018Trial
- Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study.Journal of pediatric gastroenterology and nutrition · 2026Article
- A Comparison of Biological Therapies vs Traditional Immunosuppressant in the Management of Inflammatory Bowel Diseases: A Narrative Review.Journal of community hospital internal medicine perspectives · 2026Review
- Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.Alimentary pharmacology & therapeutics · 2025Review
- Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption.British journal of clinical pharmacology · 2025Article
- Co-prescription of low-dose methotrexate and trimethoprim-sulfamethoxazole and the 30-day risk of death among older adults: A cohort study.British journal of clinical pharmacology · 2025Article
- The impact of the human gut microbiome on the treatment of autoimmune disease.Immunological reviews · 2024Review
- Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.Intestinal research · 2024Article
- Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn's Disease: A Multicenter Observational Study.Digestive diseases and sciences · 2024Observational
- Combination of Methotrexate and Resveratrol Reduces Pro-Inflammatory Chemokines in Human THP-1 Cells.Journal of inflammation research · 2024Article
- Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease.JAMA network open · 2023Article
- Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn's Disease: A Pilot Study.Biomedicines · 2023Article
- Managing Pregnancy and Nursing Affecting African American Women with Inflammatory Bowel Disease: Clinical Outcomes and Parenthood.Medical research archives · 2023Article
- Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease.Journal of Crohn's & colitis · 2022Article
- Review
- Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?Drugs & aging · 2022Review
- Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response.Inflammatory bowel diseases · 2022Review
- Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up.International journal of colorectal disease · 2022Article
- GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis.Cell · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Low-dose methotrexate (MTX) therapy is a well-recognized therapy for many inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and psoriasis. More than 20 years ago, the clinical efficacy of MTX was also established for steroid dependent Crohn's disease, but it was never broadly adapted as a treatment modality. More recently, MTX is being increasingly used in the pediatric population with Crohn's disease, both as a single agent as well as a concomitant therapy with anti-tumor necrosis factor-alpha treatment. This review outlines important pharmacological aspects for the therapeutic application of MTX and the current status of MTX as mono- or combination-therapy in both pediatric and adult patients with inflammatory bowel disease including new results of MTX monotherapy in steroid dependent ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.